Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283608 · ClinicalTrials.gov registry record
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT00283608: Completed study, sponsored by Mayo Clinic.
NCT00283608 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283608 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving anastrozole may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how anastrozole works in the body. PURPOSE: This research study is looking at the pharmacogenetics of anastrozole in postmenopausal women with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) stage I, stage II, or stage III breast cancer.
Interventions
- OTHER questionnaire administration
- OTHER high performance liquid chromatography
- GENETIC Single nucleotide polymorphism (SNP)
- OTHER measurements by DXA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2005-07 |
| Est. Completion | 2010-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283608
The ClinicalTrials.gov registry entry for NCT00283608 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which questionnaire administration is the first listed.
NCT00283608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283608 about?
NCT00283608 is a clinical study titled "Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer". RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving anastrozole may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how anastrozole works in the body. PURPOSE: This re...
What is the current status of trial NCT00283608?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2005-07. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00283608?
The interventions under investigation include: questionnaire administration (OTHER), high performance liquid chromatography (OTHER), Single nucleotide polymorphism (SNP) (GENETIC), measurements by DXA (OTHER).
Who is sponsoring clinical trial NCT00283608?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.